Rhinoviruses (RVs) are the pathogens most often responsible for the common cold, and are a frequent cause of exacerbations in asthma, chronic obstructive pulmonary disease and cystic fibrosis. Here we report the discovery of IMP-1088 , a picomolar dual inhibitor of the human N-myristoyltransferases NMT1 and NMT2, and use it to demonstrate that pharmacological inhibition of host-cell N-myristoylation rapidly and completely prevents rhinoviral replication without inducing cytotoxicity. The identification of cooperative binding between weak-binding fragments led to rapid inhibitor optimization through fragment reconstruction, structure-guided fragment linking and conformational control over linker geometry. We show that inhibition of the co-translational myristoylation of a specific virus-encoded protein (VP0) by IMP-1088 potently blocks a key step in viral capsid assembly, to deliver a low nanomolar antiviral activity against multiple RV strains, poliovirus and foot and-mouth disease virus, and protection of cells against virus-induced killing, highlighting the potential of host myristoylation as a drug target in picornaviral infections.
These authors contributed equally: Aurélie Mousnier, Andrew S. Bell. *e-mail: r.solari@imperial.ac.uk; e.tate@imperial.ac.uk R hinovirus (RV) is the pathogen most often responsible for the common cold, and is the most frequent cause of exacerbation and morbidity in important respiratory diseases, which include asthma, chronic obstructive pulmonary disease (COPD) 1 and cystic fibrosis 2, 3 . It is a member of the Picornaviridae family that includes other important human and animal pathogens, such as poliovirus (PV), foot-and-mouth disease virus (FMDV), coxsackievirus, hepatitis A virus and enterovirus 71 (EV-A71). Despite the importance of RV as a pathogen in respiratory diseases, there is no specific treatment. On the one hand, the massive RV serotypic diversity (over 100 serotypes are known) precludes the generation of broad-spectrum vaccines and, on the other hand, the rapid emergence of resistance is observed for inhibitors that target the virus itself, thanks to its rapid replication and high mutation rate 4 . The RNA genome of RV is translated by host ribosomes into a single polyprotein (Fig. 1a) , which is processed by viral proteases to form the capsid precursor protein and a number of non-structural proteins required for the completion of the viral life cycle 5 . The capsid precursor is processed further into three capsid proteins, VP0, VP3 and VP1 (Fig. 1b) , which trigger a cascade of protein selfassembly that ultimately leads to the formation of infectious virions. This cascade starts with the formation of a VP0/VP1/VP3 complex termed a protomer; five protomers assemble into pentamers, and twelve pentamers and the viral RNA genome then assemble to form an icosahedral virion 6 . The final maturation step involves cleavage of VP0 into VP4 and VP2 in the intact viral capsid.
VP0 is encoded at the N terminus of the viral polyprotein (Fig. 1a) , and in many picornaviruses it is N-myristoylated by the host cell N-myristoyltransferase (NMT). NMT undertakes the transfer of myristate from myristoyl coenzyme A (Myr-CoA) to the N terminus of a range of proteins during protein translation (that is, co-translationally), and is widely conserved across all the eukaryotic species 7 , with higher organisms, such as humans, expressing two NMT proteins (NMT1 and NMT2) in most tissues. Mutagenesis studies in PV suggest that VP0 N-myristoylation plays a role in the capsid assembly and infectivity [8] [9] [10] [11] , and host NMT may therefore be an attractive antiviral drug target that is minimally susceptible to both serotypic variation and the propensity of the virus to mutate, because host NMT is an invariant factor in viral replication.
Here we report the development of a novel class of dual human NMT1/2 (HsNMT1/2) inhibitors through a fragment reconstruction and linking approach that delivers a 100,000-fold improvement in potency, and picomolar inhibitors of the human enzymes. We use these compounds to demonstrate that the pharmacological inhibition of VP0 myristoylation by NMT in the host cell results in a specific failure to assemble virions, which leads to complete suppression of RV replication and infectivity, and we confirm the essentiality of VP0 myristoylation for RV viability through mutagenesis. We show that this mode of action is widely efficacious across multiple RV strains, in Articles NaTuRe CHeMIsTRy primary tissue models, and against PV and FMDV, and it also prevents virus-induced cytotoxicity in host cells, which indicates the potential of the human NMTs as broad-spectrum antipicornaviral drug targets.
Results
A fragment reconstruction and merging approach leads to a picomolar human NMT inhibitor. To date, NMT inhibitors, including those reported by our labs, have been developed primarily against NMT in protozoan parasites or fungi 12 , and compounds in these inhibitor series only modestly reduce protein N-myristoylation in human cells 13 . We reasoned that a new series optimized specifically against the human NMTs could deliver a greatly improved cellular activity and a tool with which to explore the anti-rhinoviral potential of NMT inhibition. During the exploration of hits from a high-throughput screen against NMT from the human malaria parasite Plasmodium falciparum 14 , we identified a novel fragmentlike compound, IMP-72 (Fig. 2a) , with weak but measurable activity against HsNMT1 (half-maximum inhibitory concentration (IC 50 ) 20 µ M). The binding mode of this fragment was initially determined in NMT from the malaria parasite P. vivax (PvNMT) in the presence of a non-hydrolysable myristoyl (NHM) CoA analogue 15 ( Fig. 2b; Supplementary Fig. 1 gives the maps for ligand electron density). IMP-72 was found to interact through its dimethylamine with the C-terminal carboxylate of the enzyme, a residue essential for catalytic activity. However, IMP-72 also makes a novel interaction through the phenyl ring to displace a tyrosine residue in the active site (Y211 in PvNMT); as this residue is conserved in human NMT (Y296 in HsNMT1), we considered IMP-72 to be a promising starting point for the development of an inhibitor of the human enzymes.
IMP-72 binds in a region complementary to a quinoline inhibitor previously reported by our labs (MRT00057965, Supplementary  Fig. 1 ) 16 and exploits distinct interactions, which suggests an opportunity for rapid optimization through fragment merging. However, on examination of the overlaid binding modes it was evident that the two fragments would clash unfavourably in the active site of the enzyme ( Supplementary Fig. 1 ). We therefore reconstructed MRT00057965 as a simplified quinoline fragment (IMP-358), which we hypothesized would recapitulate the key interaction of MRT00057965 with a conserved serine (S319 in PvNMT and S405 in HsNMT1) at the base of the pocket, without clashing with IMP-72 . At a concentration of 100 µ M this weakly binding fragment showed only a 17% inhibition of HsNMT1. However, in the presence of 100 µ M IMP-358, the potency of IMP-72 increased > 25-fold for PvNMT (to < 5 nM) and 300-fold for HsNMT1 (to 65 nM), which suggests a remarkable synergism between these distinct binding modes. The potential for cooperative binding was supported by a quaternary X-ray structure of PvNMT in complex with IMP-72 , IMP-358 and NHM, in which the fragments adopt complementary binding sites (Fig. 2c,d ). Taken together, these data suggest that the binding of IMP-72 presents an optimal cavity for the binding of IMP-358, and so delivers a synergistic inhibition ideal for fragment linking.
We next sought to replace the quinoline with a more ligandefficient motif to improve both solubility and potency, and also develop a strategy to link the fragments through the phenyl ring of IMP-72 . An ether linker combined with a trimethylpyrazole resulted in a synthetically tractable route to IMP-917 , a dual HsNMT1/2 inhibitor with a > 1,000-fold improved potency over IMP-72 (Fig. 2a) . Parallel optimization of the IMP-72 indazole core by N-methylation improved the chemical stability by reducing the potential for the elimination of dimethylamine, and also delivered a modest improvement in potency (IMP-994 (Fig. 2a) ). Inspection of the binding mode of IMP-917 in HsNMT1 with the co-substrate Myr-CoA (Fig. 2e) revealed that the first two atoms of the ether linker lie in the plane of the phenyl ring; this conformation has previously been proposed to be inherent to this motif 17 , and exerts a suboptimal interaction with HsNMT1. Moving the fluorine substituent on the phenyl ring to flank the linker yielded IMP-1031 (Fig. 3a) , a single-digit nanomolar IC 50 dual HsNMT1/2 inhibitor; crystallography confirmed that the linker is forced into an outof-plane conformation, which optimizes the interaction with S405 ( Supplementary Fig. 1 ). Finally, reintroduction of the fluorine substituent present in the original IMP-72 core resulted in IMP-1088 , a subnanomolar IC 50 inhibitor of the human N-myristoyl transferases HsNMT1 and HsNMT2 (Fig. 3a) . A high-resolution (1.88 Å) X-ray structure with HsNMT1 and the co-substrate myristoyl-CoA (Fig. 3b) shows that IMP-1088 forms an extensive network of interactions in the protein substrate pocket, which supports its unprecedented potency. Indeed, IMP-1088 is sufficiently potent to be beyond the sensitivity of enzyme inhibition assays, which suggests a tight binding in the picomolar range 18 . The difluorophenyl indazole linker takes a unique trajectory through the enzyme-active site and displaces the Y296 side chain; in this more-exposed conformation, the tyrosine ring stacks over the inhibitor, which results in a deeply buried ligand-binding mode. Furthermore, the ether linker is twisted out of plane as designed, which enables the pyrazole ring to form a strong hydrogen bond with S405, and induces an alternative conformation for H298 by comparison with IMP-917 ( Supplementary Fig. 1 ), 
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for IMP-1088 are in line with their respective HsNMT1 IC 50 values, with the latter based on an upper limit for the dissociation rate constant due to the extremely slow off rate of IMP-1088 .
Human NMT inhibitors inhibit RV capsid myristoylation in cells.
With an exceptionally potent inhibitor in hand, we next explored the impact of IMP-1088 on RV capsid myristoylation in cells using a chemical proteomic approach that takes advantage of the alkynetagged myristate analogue, YnMyr (Supplementary Fig. 3 ) 13, 19 . Metabolic labelling with YnMyr over a single-cycle 6 h synchronous infection with RV strain RV-A16 in HeLa cells (multiplicity of infection (MOI) of 20) was followed by a copper-catalysed azide-alkyne cycloaddition of protein lysate to AzTB, an azide capture reagent that bears a TAMRA fluorophore and biotin dual label ( Supplementary  Fig. 3 ) 19 . Subsequent SDS-polyacrylamide gel electrophoresis and in-gel fluorescence analysis revealed a new fluorescent band at the expected molecular weight (M w ) of VP0 (approximately 37 kDa), superimposed on a band pattern characteristic of the NMTdependent labelling of N-myristoylation in HeLa cells (Fig. 3c ) 13, 20 , which suggests that VP0 is myristoylated at 6 hours postinfection. A global identification of proteins for which myristoylation is selectively inhibited by IMP-1088 was performed by a quantitative chemical proteomic comparison of YnMyr-tagged proteins in HeLa cells infected with RV and treated with 50 nM IMP-1088 versus vehicle (dimethylsulfoxide (DMSO))-treated controls. Proteins were subjected to ligation to AzRB, an azide capture reagent that bears a trypsin-cleavable linker and biotin dual label ( Supplementary Fig. 3 ) 13, 21 , followed by affinity enrichment on NeutrAvidin beads, on-bead digestion with trypsin, nano-liquid chromatography-tandem mass spectrometry (MS/MS) analysis of tryptic peptides, and data processing by label-free protein quantification (LFQ) in MaxQuant 22, 23 . LFQ intensities across replicates were highly reproducible (R 2 = 0.96-0.98, n = 3), and permutation-based false discovery rate (FDR) two-sample t-tests were used to compare inhibitor-treated samples with controls. Multiple N-myristoylated proteins were identified in the enriched samples, including the RV polyprotein, which was significantly less enriched in the presence of IMP-1088 (Fig. 3d) . Global proteome analysis in the same samples showed no significant changes in protein abundances across the whole proteome in the presence of IMP-1088 , consistent with an NMT-inhibitor-dependent reduction in enrichment ( Supplementary Fig. 4 ). Inhibition of capsid myristoylation was further validated by Western blot with an antibody recognizing RV-A16 VP0 (Fig. 3e) , whereby the amount of tagged protein pulled down was dose-dependently reduced by IMP-1088 with the total abundance of protein remaining unaltered. The majority of viral capsid peptides identified in the pull down mapped to the VP0 domain of the polyprotein, and the N-terminal YnMyr-tagged peptide was readily identified by MS/MS ( Supplementary Figs. 5 and 6 ). These . Similar analyses were performed for the whole proteome ( Supplementary Fig. 4 ). e, Western blot and in-gel fluorescence analysis of the inhibition of VP0 myristoylation in HeLa cells infected with RV-A16 (MOI 20, 6 h) after recovery ligation to AzTB. Comparison of the input protein, supernatant after pull down on Streptavidin magnetic beads (Supnt) and eluted proteins (pull down) demonstrates an enrichment of YnMyrtagged VP0, and the specific inhibition of myristoylation. HSP90, non-myristoylated loading control.
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NaTuRe CHeMIsTRy data provide direct proteomic evidence for RV capsid myristoylation in human cells and demonstrate that this lipid modification is susceptible to inhibition by a potent NMT inhibitor.
NMT inhibition blocks the production of infectious picornaviruses and protects cells from virus-induced cytotoxicity. We next evaluated the ability of NMT inhibitors to rescue host cells from the cytopathic effect (CPE) caused by RV replication. HeLa cells were infected with RV-A16 at a low MOI (0.5) for two days, which allowed several rounds of virus replication in the presence of NMT inhibitor (or DMSO vehicle control), whereupon the cell viability was measured to quantify the virus-induced CPE. We compared IMP-1088 with the less-potent analogue IMP-1031 and found that both compounds prevented virus-induced CPE in a dose-dependent manner (Fig. 4a) , with IC 50 values of 17 nM for IMP-1088 (95% confidence interval (CI), 6.3-46 nM) and 64 nM for IMP-1031 (95% CI, 37-114 nM), in line with their relative potencies against recombinant HsNMT. In contrast, IMP-994 had no effect on CPE, as expected for a weak (9 µ M HsNMT1 IC 50 ) inhibitor (Supplementary Fig. 7 ). The absence of target engagement for this inactive control molecule in HeLa cells was further confirmed by YnMyr-tagging experiments across a wide range of concentrations, in comparison to target engagement observed for IMP-1088 at low nanomolar concentrations ( Supplementary Fig. 7) . Notably, none of these compounds had any effect on cell viability measured in parallel in uninfected cells under the same conditions ( Fig. 4b and Supplementary Fig. 7 ). This observation is in line with previous studies that showed how a low cytotoxicity during acute NMT inhibition reflects the relatively slow turnover of human NMT substrates 13, 20 , which provides a substantial window between antiviral efficacy and host-cell toxicity. The very slow off rate of IMP-1088 may result in an extended NMT inhibition in cells, with a potential risk of long-term cytotoxicity; however, this would be counteracted by recovery from inhibition through NMT resynthesis. To test the recovery from NMT inhibition, we treated HeLa cells with IMP-1088 for 24 hours, followed by washout of the compound and the measurement of in-cell NMT activity (with YnMyr) and cell viability 24 hours later ( Supplementary Fig. 8 ). NMT activity had fully recovered after 24 hours, and no cytotoxicity was detected at any time point, which confirms the capacity of cells to recover from transient NMT inhibition. 
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The effect of the more potent inhibitor (IMP-1088 ) was confirmed in a complementary assay that measured the titre of infectious virus produced in a single-cycle of infection (Fig. 4c) ; complete suppression of new infectious virus was observed at 125 nM IMP-1088 , with a similar IC 50 to that of the multicycle replication assay (5.8 nM; 95% CI, 1.6-15 nM). The antiviral potency of IMP-1088 against RV-A16 was maintained against a range of different RV serotypes (Fig. 4d) , and against the picornaviruses PV and FMDV ( Supplementary Fig. 9 ), consistent with the inhibition of a conserved and essential modification of VP0 by the host NMT. Furthermore, IMP-1088 blocked the production of infectious virus in primary human bronchial epithelial cells (hBECs), a model more representative of human infection (Fig. 4e) , and this inhibition was fully maintained during co-administration of the glucocorticoid receptor agonist fluticasone propionate, a standard inhaled corticosteroid for patients with COPD and asthma ( Supplementary Fig. 10 ) 24 . Remarkably, IMP-1088 significantly inhibited the production of infectious virus even when added up to 3 hours postinfection, which suggests that efficacy can be maintained even in the face of an active infection (Fig. 4f) .
In addition to demonstrating the impact of NMT inhibition on infectious virus production, these data strongly indicate that VP0 myristoylation is essential for the production of infectious RV particles, as previously observed for PV 8 . We generated a RV construct that allowed the expression of the RV polyprotein with a glycine at position 2 mutated to an alanine (G2A) at the N terminus to block VP0 N-myristoylation. As expected, this mutation prevented the recovery of viable virus ( Supplementary Fig. 11 ), consistent with the hypothesis that VP0 myristoylation is required for the formation of infectious virus particles.
NMT inhibition prevents assembly of intact virions. We next sought to determine the mechanism of antiviral activity. Interestingly, even though no new infectious virions are produced under NMT inhibition (Fig. 5a) , IMP-1088 blocked neither the production of viral RNA (Fig. 5b) nor the translation of RV polyprotein (Fig. 5c,d) , an outcome that was conserved in primary hBECs ( Supplementary  Fig. 12 ). These data suggest that the key step to mediate NMT inhibitor efficacy lies between protein translation and the production of infectious virions. As the processing of viral polyprotein appeared to be unaffected (Fig. 5c) , to investigate the effect of IMP-1088 on virus assembly itself we fractionated cell lysates from infected cells on a sucrose density gradient to separate viral assembly intermediates, and analysed fractions by Western blot with an anti-RV capsid antibody. In DMSO-treated controls, capsid proteins were detected in intact virion and empty capsid fractions; the latter represent capsids that have formed without packaging the RNA genome, and are commonly observed in cells that contain rapidly replicating virus. However, in IMP-1088 -treated cell lysates, capsid proteins were detected predominantly in unassembled monomer/pentamer fractions (Fig. 5e,f) and the assembled virions were essentially undetectable, which indicates that IMP-1088 blocks virus assembly. Western blot analysis of cell lysates from infected cells revealed a marked decrease in the amount of VP2 protein detected under NMT inhibition, c and d) . c, Representative images of one of three independent repeats. d, Quantification of the signal that corresponds to the 2C protein relative to a lamin B1 loading control, expressed as a percentage of 6 h of DMSO control. Error bars, s.e.m., n = 3. e, Effect of IMP-1088 on RV capsid assembly. HeLa cells were infected with RV-A16 for 6 h in the presence of IMP-1088 (500 nM) or DMSO (vehicle). Cell lysates were sedimented on sucrose density gradients and the fractions analysed by Western blot with antibodies raised against whole RV-A16 capsids. f, Densitometric analysis of e with an indication of the fractions in which controls sedimented (intact virion, empty capsid or monomer/pentamer). Supplementary Fig. 13 ). As the maturation cleavage of VP0 to generate VP4 and VP2 only occurs in fully assembled particles 25 , the absence of VP2 further supports the conclusion that NMT inhibition blocks the assembly of infectious virus.
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Discussion
The results described here establish a new series of human NMT inhibitors discovered through an unusual fragment reconstruction approach that started from two very weak HsNMT inhibitors identified in high-throughput screens against heterologous parasite targets. By leveraging the crystallographic binding modes determined in the parasite NMTs, we constructed fragment-like compounds with remarkable cooperative inhibitory effects and complementary binding modes, as revealed in the structure of a quaternary complex of both fragments with NMT and a co-substrate analogue. The perfectly poised binding modes of these fragments enabled a rapid fragment linking optimization guided by crystallography at each step, first by improving a key hydrogen-bond acceptor, and subsequently controlling the linker conformation to deliver IMP-1088, an exceptionally potent HsNMT1/2 dual inhibitor. Although the enzyme-inhibitory potency of IMP-1088 lies beyond the effective range of an enzyme-activity assay, subsequent antiviral studies in cells and SPR studies together suggest an IC 50 of approximately 200 pM for IMP-1088 against HsNMT1/2. We anticipate that IMP-1088 will be an excellent probe to enable future studies of the role of NMT and N-myristoylation in human cell and disease biology, as exemplified by the work reported here on picornaviral replication.
Multiple lines of evidence support the hypothesis that IMP-1088 effectively and potently inhibits the production of infectious RV virions by blocking RV VP0 N-myristoylation. Using a powerful chemical-tagging approach in cells infected with RV, we demonstrate a specific impact of IMP-1088 on de novo N-myristoylation of NMT substrate proteins with no impact on protein synthesis, which confirms a selective target engagement by IMP-1088 . This chemical proteomic analysis also provides direct evidence for N-myristoylation of RV VP0, which confirms it as a substrate of the host NMT. We used IMP-1088 as a chemical probe to demonstrate the critical role of VP0 myristoylation in virion assembly, particularly in the transition to intact capsids, which suggests that the myristate group is important for the aggregation of protomers and pentamers. This hypothesis is in line with genetic studies in PV [8] [9] [10] [11] , and is fully consistent with the results reported here on an RV VP0 mutant, which further supports the selectivity of IMP-1088 and provides unambiguous pharmacological evidence for NMT as a highly effective antipicornaviral target.
In keeping with its specific mode of action, NMT inhibition has no impact on viral RNA replication or polyprotein synthesis, nor does it impact host cell viability over the course of infection. Indeed, thanks to its potent antiviral activity, IMP-1088 is highly effective in protecting host cells from the cytotoxic effects of viral infection. Previous studies of the role of NMT in cancer cell lines 13, 20 support the hypothesis that the large efficacy window between host and virus is a result of substantial differences in the rate of protein turnover. At the point of inhibitor treatment, pre-existing N-myristoylated host proteins must be degraded before an impact on the cell is observed, a process that takes several days 20 compared to a matter of hours for cytotoxicity driven by RV replication. Furthermore, we have shown that NMT activity recovers rapidly after inhibitor washout, with no long-term effects on cell viability. Together these data suggest that a substantial therapeutic window might exist for a drug that targets NMT in picornaviral infections, provided dosing is undertaken near the start of the infection and does not extend beyond the few hours required to suppress replication. In the case of asthma, cystic fibrosis or COPD, we suggest that this window might be expanded by the inhaled delivery of an NMT inhibitor directly to the site of respiratory infection, and by tuning pharmacokinetics to limit the systemic stability and thus prevent the distribution of active inhibitor beyond the lung. Clearly, extensive toxicological studies are required to determine whether the benefits of efficacy and novel mode of action outweigh the potential risks of targeting the host lipidation machinery. Intervention in RV infection also needs to be coupled to diagnosis in the earliest hours postinfection, methods for which are currently lacking in the clinic. The observation that many picornaviruses have evolved to depend on host myristoylation suggests that this mode of action might circumvent the development of resistance to a drug that targets NMT because viral mutations would not influence the inhibitor potency against a host enzyme. Interestingly, the concept of targeting a core host-lipidation process to block viral replication was validated in the clinic in a phase 2A trial of an inhibitor of host prenylation of the hepatitis D virus 26 . Our data show that pharmacological NMT inhibition effects a complete inhibition of RV replication in both multicycle and single-cycle infection assays across a number of RV serotypes, in HeLa cells and in primary cells, in the presence of a standard-of-care corticosteroid for asthma and COPD, and in PV and FMDV infections. RV is the most common respiratory virus associated with pulmonary exacerbations and morbidity in asthma and COPD, and in cystic fibrosis, where patients have a high virus burden in the lungs that is associated with a worsening of their condition. The data presented here suggest that human NMT merits further investigation as a drug target in myristoylation-dependent picornavirus infections, with potential applications in the treatment of RV-induced exacerbations of asthma, COPD, cystic fibrosis and other picornaviral diseases. 
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